Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON46220
NL-OMON46220
Recruiting
Not Applicable

The Venous Congestion Validation Study - VCV study

Medisch Universitair Ziekenhuis Maastricht0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsvenous congestion1008220610057166

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
venous congestion
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
30
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • •\* Adult patients (i.e. \>18 years of age)
  • •\* Receiving right\-heart catheterization for a clinical indication

Exclusion Criteria

  • •\* Contra\-indication for MRI or unable to undergo MRI protocol due to physical condition ;\* Participation in ongoing trials for therapeutic interventions including randomized controlled trials and clinical trials of investigational medicinal products

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Venous Congestion Validation studyHeart Failure, Pulmonary hypertension, right-heart catheterization, echocardiography, MRI, hartfalen, pulmonale hypertensie, rechts kathterisatie, echocardiografie
NL-OMON22315MUMC+30
Recruiting
Not Applicable
Study to Evaluate Central venous Catheter-related Infections in Hematology and OncologyT82.7Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts
DRKS00006551niversitätsklinikum Magdeburg10,000
Recruiting
Not Applicable
Venous claudication treadmill trialVenous insufficiency. Venous claudication10014523
NL-OMON55978Erasmus MC, Universitair Medisch Centrum Rotterdam5
Not yet recruiting
Not Applicable
Clinical Performance Study Protocol for Use of VENTANA PD-L1(SP263) CDx Assay in GSK Study 213823 (GALAXIES LUNG-301)on-Small-Cell-Lung Cancer (NSCLC)locally advancedLung Cancerunresectable or metastatic NSCLC10024967
NL-OMON56986Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)10
Not yet recruiting
Phase 3
Clinical Performance Study Protocol for Use of VENTANA PD-L1 (SP263) CDx Assay in AstraZeneca Study D798AC00001(eVOLVE-Lung02): A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)Metastatic Non-Small Cell Lung Cancer with PD-L1<50%Non-Small Cell Lung Cancer10027476
NL-OMON56319Astra Zeneca32